Do analysts rate HSAQ or KRMD?

KORU Medical Systems has a consensus price target of $7.00, suggesting a potential upside of 102.90%. Given KORU Medical Systems' stronger consensus rating and higher possible upside, analysts clearly believe KORU Medical Systems is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 KORU Medical Systems 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has stronger earnings and valuation, HSAQ or KRMD?

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than KORU Medical Systems. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A KORU Medical Systems $45.11M 3.51 -$2.64M -$0.04 N/A

Do analysts prefer INGN or HSAQ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, INGN or HSAQ?

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Inogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inogen $348.67M 0.45 -$22.75M -$0.90 N/A Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

Do analysts recommend APYX or HSAQ?

Apyx Medical currently has a consensus price target of $6.60, indicating a potential upside of 118.54%. Given Apyx Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe Apyx Medical is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apyx Medical 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, APYX or HSAQ?

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Apyx Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apyx Medical $52.84M 2.41 -$11.21M -$0.20 N/A Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

Do analysts recommend HSAQ or STIM?

Neuronetics has a consensus target price of $4.50, suggesting a potential upside of 41.07%. Given Neuronetics' stronger consensus rating and higher possible upside, analysts clearly believe Neuronetics is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Neuronetics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, HSAQ or STIM?

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Neuronetics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A Neuronetics $151.64M 1.46 -$39M -$0.54 N/A

Do analysts rate OWLT or HSAQ?

Owlet presently has a consensus target price of $15.00, suggesting a potential upside of 174.78%. Given Owlet's stronger consensus rating and higher possible upside, equities research analysts plainly believe Owlet is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Owlet 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, OWLT or HSAQ?

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Owlet. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Owlet $105.70M 1.50 -$39.68M -$3.07 N/A Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

Is OWLT or HSAQ more profitable?

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Owlet's net margin of -42.54%. Company Net Margins Return on Equity Return on Assets Owlet -42.54% N/A -18.02% Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

$4.46 +0.22 (+5.19%)

As of 08/10/2026

Compare

HSAQ vs. KRMD, INGN, APYX, STIM, and OWLT

Should you buy Health Sciences Acquisitions Co. 2 stock or one of its competitors? Health Sciences Acquisitions Co. 2's main competitors and comparable companies include KORU Medical Systems (KRMD), Inogen (INGN), Apyx Medical (APYX), Neuronetics (STIM), and Owlet (OWLT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Health Sciences Acquisitions Co. 2 compare to KORU Medical Systems?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and KORU Medical Systems (NASDAQ:KRMD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

In the previous week, KORU Medical Systems had 8 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 8 mentions for KORU Medical Systems and 0 mentions for Health Sciences Acquisitions Co. 2. KORU Medical Systems' average media sentiment score of 0.45 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that KORU Medical Systems is being referred to more favorably in the news media.

Company	Overall Sentiment
Health Sciences Acquisitions Co. 2	Neutral
KORU Medical Systems	Neutral

Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, KORU Medical Systems has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to KORU Medical Systems' net margin of -4.03%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat KORU Medical Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
KORU Medical Systems	-4.03%	-10.63%	-6.51%

KORU Medical Systems has a consensus price target of $7.00, suggesting a potential upside of 102.90%. Given KORU Medical Systems' stronger consensus rating and higher possible upside, analysts clearly believe KORU Medical Systems is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than KORU Medical Systems.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A
KORU Medical Systems	$45.11M	3.51	-$2.64M	-$0.04	N/A

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Comparatively, 18.5% of KORU Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

KORU Medical Systems beats Health Sciences Acquisitions Co. 2 on 7 of the 13 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Inogen?

Inogen (NASDAQ:INGN) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Inogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.45	-$22.75M	-$0.90	N/A
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

Inogen has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

89.9% of Inogen shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 2.5% of Inogen shares are held by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Inogen's net margin of -6.94%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-6.94%	-13.17%	-8.36%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

In the previous week, Inogen had 10 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 10 mentions for Inogen and 0 mentions for Health Sciences Acquisitions Co. 2. Inogen's average media sentiment score of 0.28 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Inogen is being referred to more favorably in the media.

Company	Overall Sentiment
Inogen	Neutral
Health Sciences Acquisitions Co. 2	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Inogen beats Health Sciences Acquisitions Co. 2 on 7 of the 12 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Apyx Medical?

Apyx Medical (NASDAQ:APYX) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Apyx Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$52.84M	2.41	-$11.21M	-$0.20	N/A
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

Apyx Medical has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

In the previous week, Apyx Medical had 23 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 23 mentions for Apyx Medical and 0 mentions for Health Sciences Acquisitions Co. 2. Apyx Medical's average media sentiment score of 0.58 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Apyx Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Apyx Medical	Positive
Health Sciences Acquisitions Co. 2	Neutral

55.3% of Apyx Medical shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 15.9% of Apyx Medical shares are held by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Apyx Medical's net margin of -14.78%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Apyx Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-14.78%	-76.60%	-13.91%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

Apyx Medical currently has a consensus price target of $6.60, indicating a potential upside of 118.54%. Given Apyx Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe Apyx Medical is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Apyx Medical beats Health Sciences Acquisitions Co. 2 on 8 of the 14 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Neuronetics?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Neuronetics (NASDAQ:STIM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Neuronetics has a consensus target price of $4.50, suggesting a potential upside of 41.07%. Given Neuronetics' stronger consensus rating and higher possible upside, analysts clearly believe Neuronetics is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Neuronetics had 13 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 13 mentions for Neuronetics and 0 mentions for Health Sciences Acquisitions Co. 2. Neuronetics' average media sentiment score of 0.05 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Neuronetics is being referred to more favorably in the news media.

Company	Overall Sentiment
Health Sciences Acquisitions Co. 2	Neutral
Neuronetics	Neutral

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Neuronetics' net margin of -24.48%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
Neuronetics	-24.48%	-139.83%	-27.13%

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. Comparatively, 53.6% of Neuronetics shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Comparatively, 8.4% of Neuronetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Neuronetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A
Neuronetics	$151.64M	1.46	-$39M	-$0.54	N/A

Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Neuronetics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Summary

Neuronetics beats Health Sciences Acquisitions Co. 2 on 7 of the 13 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Owlet?

Owlet (NYSE:OWLT) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

72.6% of Owlet shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 36.2% of Owlet shares are held by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Owlet presently has a consensus target price of $15.00, suggesting a potential upside of 174.78%. Given Owlet's stronger consensus rating and higher possible upside, equities research analysts plainly believe Owlet is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Owlet	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Owlet has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

In the previous week, Owlet had 6 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 6 mentions for Owlet and 0 mentions for Health Sciences Acquisitions Co. 2. Owlet's average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score.

Company	Overall Sentiment
Owlet	Neutral
Health Sciences Acquisitions Co. 2	Neutral

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Owlet.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Owlet	$105.70M	1.50	-$39.68M	-$3.07	N/A
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Owlet's net margin of -42.54%.

Company	Net Margins	Return on Equity	Return on Assets
Owlet	-42.54%	N/A	-18.02%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

Summary

Owlet beats Health Sciences Acquisitions Co. 2 on 7 of the 11 factors compared between the two stocks.

Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSAQ vs. The Competition

Export

Metric	Health Sciences Acquisitions Co. 2	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$50.01M	$5.85B	$7.08B	$12.96B
Dividend Yield	N/A	1.76%	2.57%	10.34%
P/E Ratio	N/A	25.08	268.43	25.05
Price / Sales	N/A	62.90	596.77	89.48
Price / Cash	N/A	33.38	72.26	50.42
Price / Book	-7.19	5.89	13.21	6.18
Net Income	-$380K	$147.25M	$3.44B	$347.05M
7 Day Performance	4.45%	2.72%	2.09%	1.25%
1 Month Performance	11.78%	2.46%	-0.23%	-0.64%
1 Year Performance	64.58%	9.43%	70.30%	20.12%

Health Sciences Acquisitions Co. 2 Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HSAQ Health Sciences Acquisitions Co. 2	N/A	$4.46 +5.2%	N/A	+64.6%	$50.01M	N/A	N/A	4
KRMD KORU Medical Systems	3.8779 of 5 stars	$4.13 -2.6%	$7.25 +75.5%	-14.6%	$189.69M	$41.13M	N/A	80	Earnings Report
INGN Inogen	1.3855 of 5 stars	$6.56 -5.2%	N/A	-16.2%	$177.65M	$348.67M	N/A	1,030	News Coverage Earnings Report
APYX Apyx Medical	2.4541 of 5 stars	$4.14 -3.3%	$6.60 +59.4%	+35.4%	$173.51M	$52.84M	N/A	270	Trending News Earnings Report Analyst Revision
STIM Neuronetics	3.9611 of 5 stars	$2.35 +2.2%	$4.00 +70.2%	-18.6%	$163.54M	$149.16M	N/A	180	Trending News Earnings Report Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HSAQ) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

HSAQ vs. KRMD, INGN, APYX, STIM, and OWLT

How does Health Sciences Acquisitions Co. 2 compare to KORU Medical Systems?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Inogen?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Apyx Medical?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Neuronetics?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Owlet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSAQ vs. The Competition

Health Sciences Acquisitions Co. 2 Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

HSAQ vs. KRMD, INGN, APYX, STIM, and OWLT

How does Health Sciences Acquisitions Co. 2 compare to KORU Medical Systems?

Does the media prefer HSAQ or KRMD?

Which has more volatility and risk, HSAQ or KRMD?

Is HSAQ or KRMD more profitable?

Do analysts rate HSAQ or KRMD?

Which has stronger earnings and valuation, HSAQ or KRMD?

Do insiders & institutionals hold more shares of HSAQ or KRMD?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Inogen?

Which has preferable earnings and valuation, INGN or HSAQ?

Which has more risk and volatility, INGN or HSAQ?

Do insiders & institutionals have more ownership in INGN or HSAQ?

Is INGN or HSAQ more profitable?

Does the media favor INGN or HSAQ?

Do analysts prefer INGN or HSAQ?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Apyx Medical?

Which has higher valuation & earnings, APYX or HSAQ?

Which has more risk and volatility, APYX or HSAQ?

Does the media prefer APYX or HSAQ?

Do insiders and institutionals believe in APYX or HSAQ?

Is APYX or HSAQ more profitable?

Do analysts recommend APYX or HSAQ?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Neuronetics?

Do analysts recommend HSAQ or STIM?

Does the media favor HSAQ or STIM?

Is HSAQ or STIM more profitable?

Do insiders and institutionals have more ownership in HSAQ or STIM?

Which has higher valuation & earnings, HSAQ or STIM?

Which has more volatility and risk, HSAQ or STIM?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Owlet?

Do insiders and institutionals believe in OWLT or HSAQ?

Do analysts rate OWLT or HSAQ?

Which has more volatility & risk, OWLT or HSAQ?

Does the media refer more to OWLT or HSAQ?

Which has better valuation and earnings, OWLT or HSAQ?

Is OWLT or HSAQ more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSAQ vs. The Competition

Health Sciences Acquisitions Co. 2 Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools